Kafkas Nikolaos V, Patsilinakos Sotirios P, Mertzanos George A, Papageorgiou Kostas I, Chaveles John I, Dagadaki Ourania K, Kelesidis Kostas M
Cardiology Department of General Hospital Att. KAT, Greece.
Int J Cardiol. 2007 Jun 12;118(3):321-5. doi: 10.1016/j.ijcard.2006.07.017. Epub 2006 Oct 17.
The aim of our study was to compare the efficacy and safety of ibutilide and amiodarone (intravenously) in converting recent-onset atrial fibrillation (AF) and atrial flutter (Af) to sinus rhythm (SR).
The study was prospective, randomized and included 152 (103 men and 49 women) consecutive patients with AF or Af of 3-48 h duration. Ibutilide is a selective class III antiarrhythmic agent which when administered intravenously can terminate AF and Af. Amiodarone is also a class III antiarrhythmic agent that when given intravenously or orally has proved to be more effective than other agents in terminating AF and Af [B.N. Singh, F.V. Mody, B. Lopez, J.S. Sarma. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. Am J Cardiol 1999 Nov 4; 84: 161R-173R.]. Seventy-nine patients (56 with AF and 23 with Af) that consisted group A were treated with ibutilide. Seventy-three (52 with AF and 21 with Af) consisted group B and were treated with intravenous infusion of amiodarone.
The conversion rate of group A (ibutilide) was significantly higher than the conversion rate of group B (amiodarone) (80% vs. 57%, p=0.0054). As regards the kind of arrhythmia separately, for AF there wasn't significant difference (77% vs. 69%, p=ns) whereas for Af ibutilide was superior to amiodarone (87% vs. 29%, p=0.003). The conversion rates of ibutilide didn't differ for AF and Af (77% vs. 87%, p=ns).
Ibutilide is more effective than amiodarone in converting recent-onset Af to SR whereas both drugs are equally effective in converting recent-onset AF to SR.
本研究旨在比较静脉注射伊布利特和胺碘酮转复近期发作的心房颤动(AF)和心房扑动(Af)为窦性心律(SR)的疗效和安全性。
本研究为前瞻性、随机研究,纳入了152例(103例男性和49例女性)持续时间为3 - 48小时的AF或Af连续患者。伊布利特是一种选择性III类抗心律失常药物,静脉给药时可终止AF和Af。胺碘酮也是一种III类抗心律失常药物,静脉或口服给药时,已证明在终止AF和Af方面比其他药物更有效[B.N.辛格、F.V.莫迪、B.洛佩斯、J.S.萨尔马。用于心房颤动的抗心律失常药物:关注延长心房复极。《美国心脏病学杂志》1999年11月4日;84:161R - 173R]。79例患者(56例AF和23例Af)组成A组,接受伊布利特治疗。73例(52例AF和21例Af)组成B组,接受静脉输注胺碘酮治疗。
A组(伊布利特)的转复率显著高于B组(胺碘酮)(80%对57%,p = 0.0054)。就心律失常类型分别而言,对于AF没有显著差异(77%对69%,p =无统计学意义),而对于Af,伊布利特优于胺碘酮(87%对29%,p = 0.003)。伊布利特对AF和Af的转复率没有差异(77%对87%,p =无统计学意义)。
在将近期发作的Af转复为SR方面,伊布利特比胺碘酮更有效,而在将近期发作的AF转复为SR方面,两种药物同样有效。